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Abstract
Canonical Wnt signals are transduced through a Frizzled receptor and either the LRP5 or LRP6 co-receptor; such signals play
central roles during development and in disease. We have previously shown that Lrp5 is required for ductal stem cell activity
and that loss of Lrp5 delays normal mammary development and Wnt1-induced tumorigenesis. Here we show that canonical
Wnt signals through the Lrp6 co-receptor are also required for normal mouse mammary gland development. Loss of Lrp6
compromises Wnt/b-catenin signaling and interferes with mammary placode, fat pad, and branching development during
embryogenesis. Heterozygosity for an inactivating mutation in Lrp6 is associated with a reduced number of terminal end
buds and branches during postnatal development. While Lrp6 is expressed in both the basal and luminal mammary
epithelium during embryogenesis, Lrp6 expression later becomes restricted to cells residing in the basal epithelial layer.
Interestingly, these cells also express mammary stem cell markers. In humans, increased Lrp6 expression is associated with
basal-like breast cancer. Taken together, our results suggest both overlapping and specific functions for Lrp5 and Lrp6 in the
mammary gland.
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Introduction
Wnt signaling plays key roles in embryogenesis and in adult tissue
homeostasis of metazoan animals [1]. The extracellular Wnt signal
stimulates numerous intracellular signal transduction cascades,
including the canonical Wnt/b-catenin pathway, which regulates
gene expression in the nucleus, and a number of noncanonical
pathways, which regulate many other aspects of cellbiology including
cell migration, adhesion, and polarity [2–4]. Mutations of the genes
involved in Wnt signaling cause congenital defects in humans, and
inappropriate activation of the Wnt/b-catenin pathway has been
linked to the development of human cancer [5–7]. An increasing
number of studies have shown that Wnt/b-catenin signaling regulates
the self-renewal and differentiation of adult stem cells, raising the
possibility that this process is subverted in cancer [8–10].
Activation of the Wnt/b-catenin pathway is initiated by the
binding of Wnt proteins to cell surface receptors composed of a
member of the Frizzled (Fzd) protein family and one of the two low-
density lipoprotein receptor–related proteins, LRP5 or LRP6
(reviewedin[11]).SignalingfromWntreceptorsleadstoinactivation
of a cytoplasmic protein complex that normally catalyzes the
phosphorylation and subsequent destruction of b-catenin. Canonical
Wnt signaling thus induces stabilization of cytosolic b-catenin. A
fraction of b-catenin then enters the nucleus, binds to transcription
factors such as those of the LEF-1/TCF family, and modulates the
transcription of specific target genes (see The Wnt Homepage at
http://www.stanford.edu/,rnusse/wntwindow.html).
The initiation of canonical Wnt/b-catenin signaling requires
LRP5 or LRP6 [12–14]; in contrast, noncanonical Wnt pathways
are usuallyindependentofthese twoproteins [3,4].LRP5and LRP6
are highly homologous and exhibit functional redundancy both in
vitro and in vivo [14–17]. However, loss-of-function studies in animals
show that Lrp5 and Lrp6 also have unique roles for which the other
cannot compensate. In mice, disruption of Lrp6 causes severe
developmental defects [13]. The defects reflect a composite of some
of the Wnt mutant phenotypes and include a deletion of caudal
midbrain, axis truncation, and limb patterning defects. Neonatal
lethality prevents a thorough analysis of the consequences of Lrp6
deficiency in the adult mouse. Disruption of Lrp5 does not cause
gross developmental abnormalities, but abnormalities have been
identified in a number of different tissues [17–20]. We have
previously shown that Lrp5 is required for ductal stem cell activity,
which isapparent by the failureofLrp5
2/2 mammary epithelial cells
to colonize in transplantation experiments [21]. Consequently, loss
of Lrp5 is associated with delayed mammary gland development and
Wnt1-induced tumorigenesis [21]. Here we show that canonical
Wnt signals through the Lrp6 co-receptor are also required for
normal mammary gland development.
Results
Lrp6 expression in the mammary gland
The targeting vector used to create the Lrp6
2/2 mouse strain
contained the b-galactosidase (b-gal) gene. As a result, b-gal
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5813expression is directed from the Lrp6 promoter in Lrp6
+/2 and
Lrp6
2/2 mice and can be used as a surrogate marker for Lrp6




In order to determine the expression pattern of Lrp6 in the
mammary gland, we first stained mammary whole mounts from
Lrp6
+/2 and Lrp6
+/+ females of different ages (newborn, juvenile 5-
week, adult 12-week, and days 12.5 and 18.5 of pregnancy) with
X-gal. b-gal expression was detected in the Lrp6
+/2 mammary
epithelium, stroma, and fat pad at all analyzed time points
(Fig. 1A–B and data not shown). However, the expression pattern
differed between mammary glands collected from newborn
females versus glands collected from juvenile, adult, and pregnant
females. The mammary epithelium contains a basal cell layer of
mostly myoepithelial cells and a luminal cell layer of keratin 8/18–
positive epithelial cells. During embryogenesis and until a few days
after birth, b-gal expression was detected in both the basal and
luminal mammary epithelium (Fig. 1A). In juvenile, adult, and
pregnant females, however, b-gal expression was primarily seen in
cells residing within the basal epithelial cell layer of mammary
glands (Fig. 1B). Abundant Lrp6 expression was seen in the
mammary fat pad at all developmental time points analyzed
(Fig. 1A–B and data not shown). Lrp6
+/+ mammary whole mounts
were used as a negative control for the X-gal staining (Fig. 1A–B).
To further characterize the expression pattern of Lrp6 in the
adult mammary epithelium, we performed fluorescence-activated
cell sorting (FACS) analysis on single-cell suspensions isolated from
mammary glands of 3-month-old Lrp6
+/2 and Lrp6
+/+ females.
Because hematopoietic and stromal cells can make up at least 50%
of such cell suspensions, we first removed cells expressing cell
surface antigens of hematopoietic and endothelial origin (CD45,
Ter119, and CD31). The epithelial cell–enriched fractions were
then labeled with the CD24 (heat-stable antigen) and CD49f (a6
integrin) cell surface antigens. We used the fluorescent b-gal
substrate DDAOG [22] to detect cells that express Lrp6. The basal
and luminal epithelial subpopulations, as well as a cell fraction
enriched for mammary stem cells, can be visualized by the relative
expression of CD24 and CD49f [23,24] (Fig. 1C). In concordance
with the X-gal staining, we found by FACS that the majority of
DDAOG-positive cells resided in the basal subpopulation (Fig. 1D).
These DDAOG-positive cells expressed the highest levels of
CD49f and moderate levels of CD24 (Fig. 1C–D). This
observation was of particular interest because mammary epithelial
cells with stem cell properties typically exhibit this expression
pattern [23]. Lrp6
+/+ mammary epithelial cells were used as a
negative control for the DDAOG staining (Fig. 1F).
Impaired mammary development in Lrp6
2/2 embryos
Lrp6
2/2 mice die shortly after birth. To determine the effect of
Lrp6 deficiency on the rudimentary mammary gland that develops
by birth, we collected ventral skin from Lrp6
2/2 (n=5)andLrp6
+/+
(n=10) embryos at E18.5. Normally at this stage, the mammary
gland is composed of a ductal tree consisting of a primary duct with
secondary and tertiary branches surrounded by a fat pad. We found
that the while all 10 mammary glands were present in Lrp6
2/2
embryos, they were underdeveloped. The nipples were considerably
smaller than those of littermate controls and the mammary
epithelium typically consisted of a single duct (Fig. 2A). In a minority
of inguinal Lrp6
2/2 mammary glands, the epithelium formed two
shortbranches at the extremity of the mainduct(not shown). During
dissection and carmine staining we noticed that the adipose tissue
forming the fat pad was abnormally small and underdeveloped in
Lrp6
2/2 embryos (Fig. 2B). In contrast, all Lrp6
+/+ mammary glands
showed secondary and tertiary branches surrounded by a fat pad
(Fig. 2A–B).
The ductal tree at E18.5 evolves from the epithelial mammary
placode, which has formed by E12.5. To determine whether Lrp6-
mediated Wnt signaling is required for the development of
mammary placodes, we analyzed Lrp6
2/2 and Lrp6
+/+ littermate
whole embryos at E12.5. To assess the activity of Wnt/b-catenin
signaling pathway in this context, we intercrossed Lrp6
+/2 mice to
BAT-gal transgenic mice. BAT-gal mice carry a reporter gene
which contains a b-gal gene under the transcriptional control of
LEF/TCF sites [25]. It is important to note that b-gal expression
induced by BAT-gal reporter gene activity can be discriminated
from b-gal expression induced by Lrp6 promoter activity due to a
large difference in the time it takes to detect the b-gal by X-gal
staining. While BAT-gal-associated b-gal expression is detected
within 20 minutes of X-gal staining, Lrp6-associated b-gal
expression is not detected until after several hours of X-gal
staining. Our results showed that loss of Lrp6 compromised Wnt/
b-catenin signaling in the developing mammary placodes and
interfered with their formation. BAT-gal reporter gene activity was
significantly reduced in Lrp6
2/2 embryos relative to littermate
controls (Fig. 2C). On the histological level, the mammary
placodes of Lrp6
2/2 embryos were significantly smaller and
contained fewer cells with reporter gene activity (Fig. 2D).
Postnatal mammary development in Lrp6
+/2 females
To determine if the loss of one allele affects postnatal mammary
development, we collected and examined inguinal mammary
whole mounts from juvenile (5-week) and adult (11-week) Lrp6
+/2
and Lrp6
+/+ female littermates. No differences in ductal extension
were found at 5 weeks (Fig. 3A). However, the number of terminal
end buds (TEBs) was significantly reduced in Lrp6
+/2 mammary
glands (Fig. 3A–B). TEBs are club-shaped epithelial thickenings at
the distal ends of growing ducts and are the sites of the most rapid
cell proliferation. We found that the number of TEBs was reduced
by 33% in juvenile Lrp6
+/2 mice compared with littermate wild-
type mice (p=1.3610
26). The branching complexity in adult mice
is a function of terminal end bud activity during juvenile ductal
extension. Morphometric analysis showed that the branching
complexity of 11-week-old Lrp6
+/2 glands was decreased by 17%
compared with that of littermate wild-type mice (p=8.4610
23)
(Fig. 3C). We measured the weight of Lrp6
+/2 and Lrp6
+/+
mammary fat pads but no difference was detected (data not
shown).
We next tested whether the Lrp6
+/2 ductal phenotype would
become more or less apparent after transplantation of epithelial
cells into wild-type mammary glands. For this purpose we
transplanted 5,000 Lrp6
+/2 or Lrp6
+/+ mammary epithelial cells
into the cleared fat pads of 21-day-old immune-compromised
Rag2-deficient females. Out-growths were found in 5/8 and 6/8
fat pads transplanted with Lrp6
+/2 and Lrp6
+/+ mammary
epithelial cells, respectively. The branching morphology was
similar in host fat pads six weeks after surgery regardless of
transplant genotype (Fig. 3D). None of the 4 Rag2-deficient control
mice whose fat pads (n=8) were cleared but not injected with
mammary epithelial cells contained ductal out-growths, confirm-
ing our ability to successfully clear the mammary fat pad (Fig. 3D).
We also examined the effect of compound mutations of Lrp6 and





genotypes die during embryogenesis, some Lrp6
+/2;Lrp5
2/2 mice
live into adulthood. Lrp6
+/2;Lrp5
2/2 mice have limb deformities
and 80% dieshortlyafterbirth, butsurviving pupshavea normal life
span and are fertile [16,17]. We dissected the mammary glands from
Lrp6 in the Mammary Gland
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5813Figure 1. Expression pattern of Lrp6 in the mammary gland. b-gal expression directed from the Lrp6 promoter in Lrp6
+/2 mice was used as a
surrogate marker for Lrp6 expression. We used the b-gal substrates X-gal and DDAOG to identify cells that express Lrp6. Shown in (A-B) are X-gal-
stained mammary whole mounts and 5-mm sections from 2-day-old (A) and 12-week-old (B) female mice. (A) Lrp6 promoter-driven b-gal expression is
visible as blue staining in both the basal and luminal mammary epithelium and in the mammary fat pad of newborn mice. (B) In older mice, b-gal-
expressing cells are primarily identified within the basal epithelial cell layer and in the mammary fat pad. The arrows indicate typical cells that stained
blue with X-gal. No staining was detected in Lrp6
+/+ mammary glands, which were used as negative controls for X-gal staining. (C-F) Representative
FACS results of DDAOG-stained and CD24/CD49f antibody–labeled mammary epithelial cells. The b-gal-cleaved product of DDAOG has far-red
fluorescence and was used to detect cells with Lrp6 promoter–driven b-gal expression. (C) The luminal and basal cell compartments are marked by
pink and blue dashed lines, respectively. (D) 80% of the DDAOG-positive cells are found within the basal epithelial cell compartment. (E-F) DDAOG
Lrp6 in the Mammary Gland
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+/2;Lrp5
2/2 female carcasses previously studied
for their bone phenotype. Although nipples and normal size fat pads
were visible upon dissection, none of the 5 analyzed animals had
ductal tree outgrowths in any of their 10 mammary glands (Fig. 3E).




Female mice that express Wnt1 under the mammary-specific
MMTV promoter reproducibly develop mammary adenocarci-
nomas within one year [26]. The tumors develop in a context of
widespread hyperplasia that is noticeable as early as E18.5. To test
whether transgenic expression of Wnt1 could induce ductal side-
branching in Lrp6
2/2 embryos and to determine the requirement
for Lrp6 in Wnt1-induced tumorigenesis, we intercrossed Lrp6
+/2
and MMTV-Wnt1 mice. We found that transgenic expression of
Wnt1 partially rescued the Lrp6
2/2ductal phenotype at E18.5 and
induced sprout elongation and side-branching (Fig. 4A). The
inguinal mammary epithelial tree of MMTV-Wnt1;Lrp6
+/+ (n=6)
and MMTV-Wnt1;Lrp6
2/2 (n=4) embryos contained on average
10 and 4 end buds, respectively. The MMTV-Wnt1;Lrp6
2/2
mammary nipples and fat pads were still abnormally small.
Furthermore, no obvious reduction in mammary hyperplasia was
observed, and tumor onset was only slightly delayed in adult
MMTV-Wnt1;Lrp6
+/2 females (p=0.08) (Fig. 4B–C). Histopatho-
logical examination showed that all tumors, regardless of Lrp6
genotype, were moderately differentiated alveolar mammary
adenocarcinomas (Fig. 4D).
Increased Lrp6 expression in human basal-like breast
cancer
Global gene expression analyses of human breast cancers have
identified four major tumor subtypes and a normal breast tissue
group [27–29]. Two subtypes are estrogen receptor (ER)–negative
and have poor patient outcomes: one of these two subtypes is
defined by the high expression of HER2, and the other shows
characteristics of basal/myoepithelial cells (basal-like). The
remaining two subtypes, luminal subtype A or B, are ER-positive
and Keratin 8/18–positive. We looked at the expression pattern of
Lrp6 in two published transcriptome profiles of breast cancer. The
first study, led by Livingston and Ganesan at Harvard Medical
School, contained 45 samples (18 Basal-like, 20 non-Basal, and 7
Normal) [30] (Fig. 5A) and the second, led by Perou at the
University of North Carolina, contained 213 samples (64 Basal-
like, 30 HER+, 70 Luminal A, 31 Luminal B, and 18 Normal
Breast-like) [31] (Fig. 5B). We found that increased expression of
Lrp6 was associated with basal-like breast cancer (p=1.8610
–4,
p=9.6610
–5) (Fig. 5A–B). In fact, a fraction of samples within the
basal-like subgroup of both studies expressed levels of Lrp6 not
seen in any of the other subgroups or the normal controls.
Interestingly, we also found a correlation between Lrp5 expression





Wnt signaling pathways play essential roles at multiple steps of
animal development, including embryonic induction, organogen-
esis, and adult tissue homeostasis. The binding of Wnt ligands to a
receptor complex composed of one Frizzled (Fzd) protein and
either LRP5 or LRP6 initiates the Wnt/b-catenin cascade. At the
cellular level, Wnt/b-catenin signaling regulates a broad range of
functions, including the self-renewal and differentiation of stem
cells. We have previously shown that Lrp5 is critical for mammary
ductal stem cell activity: its loss is associated with impaired
mammary gland development and delayed Wnt1-induced mam-
mary tumorigenesis [21]. Here, we show that Lrp6 is also required
for normal mammary gland development. Loss of Lrp6 impairs
embryonic mammary development, evident by abnormal mam-
mary placode development at E12.5 and the absence of ductal
branching and fat pad development at E18.5 (Fig. 2A–D).
Furthermore, postnatal mammary development is affected in
Lrp6 heterozygote females: the number of TEBs and ductal
branches are reduced in juvenile and adult mice, respectively
(Fig. 3A–C). Although it is not yet clear whether Lrp6 is required
for ductal stem cell activity, we found that Lrp6 is expressed by
epithelial cells within the basal cell layer that also express stem cell
markers (Fig. 1B–D). Finally, an increased expression of Lrp6 is
associated with human basal-like breast cancer (Fig. 5A–B). Taken
together with our previous study, our results show that both Lrp5
and Lrp6 play essential roles in the mammary gland development
and cannot fully compensate for each other’s loss.
The initial stages of mammary development are hormone-
independent, depending instead on reciprocal signaling between
the epithelium and the mesenchyme (reviewed in [32–34]).
Mammary gland development begins at about embryonic day
10.5 with the appearance of the mammary lines. In response to
signals from the underlying mesenchyme, the mammary lines give
rise to five pairs of lens-shaped mammary placodes that
subsequently invaginate into the underlying dermal mesenchyme,
forming mammary buds. In females at E15.5, the buds elongate
and form a mammary sprout that extends towards the fat pad
precursor mesenchyme. Mammary nipples are formed around
E16.5. Meanwhile the epithelial sprout branches into the fat pad
precursor mesenchyme, resulting in the formation of a rudimen-
tary ductal tree prepared to respond to hormonal cues at puberty.
Studies using Wnt reporter gene mouse strains have shown that
activation of the Wnt/b-catenin signaling pathway along the
mammary lines coincides with the initiation of mammary
morphogenesis and subsequently localizes to the mammary
placodes, buds, and rudimentary ductal tree [21,35,36]. Further-
more, Wnt signaling appears to be required for embryonic
mammary development: embryos deficient for Lef1 fail to
develop/maintain their mammary placodes, and embryos that
express the Wnt inhibitor Dkk1 in developing epithelium fail to
form mammary placodes [37,38]. Dkk1 inhibits the Wnt signaling
pathway by binding to (and presumably inactivating) Lrp5 and
Lrp6 [39]. In agreement, embryos lacking Lrp5 exhibit reduced
Wnt/b-catenin signaling and have significantly smaller mammary
placodes than littermate wild-type controls [21]. Despite the
placode phenotype, the rudimentary ductal tree and fat pad
develop normally in Lrp5
2/2 embryos.
At E12.5, the phenotype of Lrp6
2/2 embryos is similar to that of
Lrp5
2/2 embryos, the mammary placodes are smaller, abnormally
developed, and contain few cells with activated Wnt/b-catenin
signaling relative to wild-type controls (Fig. 2C–D). However, in
contrast to Lrp5
2/2 embryos, the rudimentary ductal tree fails to
develop in Lrp6
2/2embryos (Fig. 2A). It is not clear if this
phenotype is due to an inadequacy of the mammary epithelium
or/and the fat pad. Signals from the fat pad mesenchyme play a
gating strategy. The DDAOG gate is indicated by the black line. The Lrp6
+/2 sample (E) has 0.33% DDAOG-positive cells; the Lrp6
+/+ negative control
sample (F) has 0.01% DDAOG-positive cells.
doi:10.1371/journal.pone.0005813.g001
Lrp6 in the Mammary Gland
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PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5813central role for ductal elongation and branching and may be
diminished in the absence of Lrp6 [32–34]. Lrp6 is normally
expressed both in the mammary epithelium and fat pad, and the
loss of Lrp6 is associated with abnormal development of both
compartments. The MMTV-Wnt1;Lrp6 cross showed that Lrp6
2/2
mammary epithelium is not incapable of further development,
since transgenic expression of MMTV-Wnt1 produced sprout
elongation and branching despite the presence of underdeveloped
fat pads (Fig. 4A). This suggests that the dose of Wnt/b-catenin
signaling within the mammary epithelium is critical and can
determine the degree of embryonic ductal development. In further
support of this, Lrp6
+/2;Lrp5
2/2 female mice fail to develop
mammary ducts (Fig. 3E).
We have previously shown that Lrp5 is required for Wnt1-
induced mammary tumorigenesis [21]. Tumor onset is dramati-
cally delayed in MMTV-Wnt1;Lrp5
2/2 and MMTV-Wnt1;Lrp5
+/2
females. The effect of Lrp6 heterozygosity was much less
pronounced. The average time of tumor onset was delayed by 6
and 17 weeks in Lrp6
+/2 and Lrp5
+/2 mice, respectively (Fig. 4C
and [21]). Lrp6 heterozygosity slightly delayed the time at which
tumors first appeared, but the rate of tumor onset was then similar
between Lrp6
+/2 and Lrp6
+/+ females (Fig. 4C). Consistent with
this, we saw no reduction in mammary hyperplasia in adult
MMTV-Wnt1;Lrp6
+/2 females (Fig. 4B). Relatively little is known
of the ligand-receptor specificity exhibited by different Wnts, Fzds,
and LRPs in Wnt signaling. However, our results suggest that
Lrp5 plays a pivotal role over Lrp6 in transmitting oncogenic Wnt
signals in the MMTV-Wnt1 mammary tumor model.
Wnt/b-catenin signaling is a key regulator of embryonic and
somatic stem cells [9,10]. In the adult mouse, Wnt/b-catenin
signaling has been shown to regulate a number of epithelial stem
cell compartments, including those of the skin, gut, and mammary
gland [40–44]. Mammary epithelial cells with stem cell activity,
i.e., cells that can develop a functional ductal tree in single cell
transplantation experiments, can be identified by FACS [23,45].
These cells typically express moderate and high levels of the cell
surface markers CD24 and CD49f, respectively [23]. Interestingly,
most Lrp6-expressing mammary epithelial cells exhibited this
expression pattern (Fig. 1C–D). Furthermore, mammary stem cells
are presumed to reside within the basal cell layer of the mature
mammary ducts [23,46,47], and this is where Lrp6-expressing cells
primarily were identified (Fig. 1B). We also found that human
basal-like breast cancers are associated with increased Lrp6
expression, suggesting that these tumors may be enriched with
Lrp6-expressing cells. Subpopulations of cancer cells with stem cell
properties are especially frequent within basal-like breast cell lines
and show increased tumorigenic and invasive potential [48,49].
Whether Lrp6 is required for ductal stem cell activity remains to
be determined, as does the role of Lrp6-mediated Wnt signaling in
the mammary fat pad. Development of conditional mouse models
for Lrp6 and Lrp5 deletion will aid in the understanding of the
specific roles of these proteins in mammary gland development
and tumorigenesis. This is particularly important because Wnt/
b-catenin signaling is often activated in human breast cancer. At
least 50% of human breast cancers exhibit nuclear/cytoplasmic b-
catenin, and aberrant activation of the pathway at the receptor
level is common [9,50–52]. Hence, therapeutic interventions
targeting LRP5 and/or LRP6 could be useful in treating some
types of breast cancer, particularly the basal-like class for which
few, if any, effective treatments exist.
Materials and Methods
Mouse strains and husbandry
Lrp6 (C57Bl/6J) knock-out mice, as well as BAT-gal (FVB/N)
and MMTV-Wnt1 (FVB/N) transgenic mice, have been previously
described [13,25,26]. PCR-based strategies were used to genotype
these mice (details available upon request). All experiments
performed were approved in advance by the Van Andel Research
Institute Institutional Animal Care and Use Committee. To assay
the appearance of mammary tumors, the mice were inspected
three times a week and were euthanized when tumors appeared.
Mammary gland morphogenesis
Whole mounts were prepared as described [53]. Briefly,
inguinal mammary glands were dissected, fixed overnight in
Carnoy formula (6:3:1 ratio of ethanol:chloroform:glacial acetic
acid), rehydrated, and stained overnight in Carmine alum stain.
The stained glands were dehydrated, cleared in xylene, and stored
in Methyl Salicylate. After whole-mount pictures had been taken,
the tissues were embedded in paraffin for sectioning. Sections
(5 mm) were rehydrated and counterstained with H&E.
Oil red O staining
Ventral skin pads were placed in propylene glycol for 2 min and
then in Oil red O stain heated to 60uC for 6 min, followed by 85%





+/+ (negative control) mammary glands and
12.5-day-old embryos were isolated and fixed in 0.25%
glutaraldehyde, 2% formaldehyde, 5 mM EGTA, and 2 mM
MgCl2 in PBS pH 7.4 at 4uC. Mammary glands were fixed for
2 h; embryos for 1 h. Glands and embryos were then rinsed
twice in 2 mM MgCl2, 0.1% sodium deoxycholate, and 0.2%
NP40 in PBS at room temperature for 1 h and then were stained
in X-gal buffer (1 mg/ml X-gal, 2 mM MgCl2, 0.01% sodium
deoxycholate, 0.02% NP-40, 5 mM Fe3(CN)6,5m MF e 4(CN)6
in PBS) at 30uC. Lrp6
+/2 mammary glands were stained
overnight; BATgal transgenic embryos were stained for 20 min.
The whole mounts were then rinsed in PBS, dehydrated, and
cleared in xylene. After whole-mount pictures had been taken,
the tissues were immediately embedded in paraffin for section-
ing. Sections (5 mm) were counterstained with 0.1% nuclear fast
red or eosin. A minimum of three animals per genotype and time
point were analyzed.
Figure 2. Lrp6 is required for embryonic mammary development. (A) Carmine-stained skin pads of inguinal mammary glands at E18.5. While
in the Lrp6
+/+ mammary gland the nipple, rudimentary ductal tree, and fat pad are all normally developed, the Lrp6
2/2 mammary gland contains a
small nipple, a single ductal out-growth, and an abnormally small fat pad. Dashed lines indicate inguinal epithelium. (B) Oil red O staining of
mammary fat pads from Lrp6
+/+ and Lrp6
2/2 embryos. The Lrp6
2/2 fat pad is abnormally small compared to that of the littermate control. Scale bar:
0.5 mm. (C-D) X-gal-stained BAT-gal embryo whole mounts (C) and histology sections of mammary placode (D) at E12.5. Cells expressing BAT-gal are
stained blue. (C) X-gal stains the mammary placodes of BAT-gal;Lrp6
+/+ embryos dark blue. Arrow heads indicate mammary placodes number 2, 3, 4,
and 5. Mammary placodes are not readily visible on X-gal-stained BAT-gal;Lrp6
2/2 embryo whole mounts. (D) On the histological level, the mammary
placodes of BAT-gal;Lrp6
2/2 embryos are significantly smaller and exhibit fewer cells with BAT-gal expression than the mammary placodes of
littermate controls. Dashed lines indicate inguinal placodes.
doi:10.1371/journal.pone.0005813.g002
Lrp6 in the Mammary Gland
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5813Lrp6 in the Mammary Gland
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e5813Figure 3. Haploinsufficiency for Lrp6 in postnatal mammary development. (A) Representative mammary whole-mount preparations are
shown for juvenile (5-week-old) mice. The arrows indicate typical terminal end buds; LN, lymph node. (B) The result of morphometric analysis of the
average number of TEBs at 5 weeks and (C) of branches per gland at 11 weeks. At least 10 animals of each genotype were analyzed for each time
point. In the absence of one copy of Lrp6, the number of TEBs is reduced by 33% (p=1.3610
26, 2-tailed t test assuming unequal variances), and the
number of branches per gland is reduced by 17% (p=8.4610
23, 2-tailed t test assuming unequal variances) compared with Lrp6
+/+ littermate
controls. (D) Mammary whole mounts containing ductal colonization originating from transplanted Lrp6
+/+ or Lrp6
+/2 mammary epithelial cells. Also
shown is a transplantation control whose inguinal fat pads were cleared of endogenous epithelium but not injected with mammary cells. (E) The
inguinal mammary gland from an adult Lrp6
+/2;Lrp5
2/2 female. The mammary gland contains a fat pad and a nipple with associated epithelium but
lacks a ductal tree. Box indicates the nipple epithelium.
doi:10.1371/journal.pone.0005813.g003
Figure 4. Wnt1-induced mammary tumorigenesis in Lrp6
+/2 females. Shown in (A-B) are representative carmine stained skin pads and
mammary whole mounts. (A) Skin pads collected from E18.5 MMTV-Wnt1;Lrp6
+/+ and MMTV-Wnt1;Lrp6
2/2 embryos. (B) Mammary whole mounts
collected from adult MMTV-Wnt1;Lrp6
+/+ and MMTV-Wnt1;Lrp6
+/2 females. (C) The percentages of MMTV-Wnt1;Lrp6
+/+ (n=12) and MMTV-Wnt1;Lrp6
+/2
mice (n=13) that were tumor-free (as determined by weekly visualinspectionand/or palpation) were plotted against the age when tumors were found.
(D) Standard histopathological evaluation showed that all Lrp6
+/+ and Lrp6
+/2 MMTV-Wnt1 tumors are moderately differentiated alveolar mammary
adenocarcinomas.
doi:10.1371/journal.pone.0005813.g004
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Mammary glands were dissected and minced with scissors, then
the cells were dissociated for 8 h at 37uC in EpiCult-B with 5%
fetal bovine serum, 300 units/ml collagenase, and 100 units/ml
hyaluronidase. After vortexing and lysis of the red blood cells in
NH4Cl, a single-cell suspension was obtained by sequential
dissociation of the fragments by gentle pipetting for 1–2 min in
0.25% trypsin and then for 2 min in 5 mg/ml Dispase II plus
0.1 mg/ml DNase I, followed by filtration through a 40-mm mesh.
All reagents were from StemCell Technologies Inc.
Mammary transplantation assays
Viable mammary epithelial cells collected from 3-month-old
Lrp6
+/2 (n=5) and Lrp6
+/+ (n=3) virgin female mice were counted
on a hemocytometer, suspended at the desired concentration in
1:1 PBS:Matrigel (BD Biosciences) together with 0.5% trypan blue
Figure 5. Increased Lrp6 expression in basal-like human breast cancer. The relative expression of Lrp6 in breast cancer samples analyzed by
Affymetrix and organized into defined subgroups. Each dot represents the relative expression of Lrp6 in one tumor sample. (A) Expression data was
obtained from [30]. Normal includes samples obtained from normal breast tissue. (B) Expression data was obtained from [31]. Normal Breast-like
includes samples obtained from normal and cancerous breast tissue that exhibited expression profiles similar to that of normal breast tissue. A subset
of breast cancers within the basal-like subgroup of both studies exhibit increased expression of Lrp6.
doi:10.1371/journal.pone.0005813.g005
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injected in a total volume of 10 ml into contralateral cleared fat
pads of the #4 mammary glands of 21-day-old female Rag2
2/2
mice using a Hamilton syringe [54]. Six or 12 weeks after
transplantation, the fat pads were dissected, processed, and stained
with carmine as described above.
Fluorescence-activated cell sorting
Mammary epithelial cells were isolated as described above. The
Mouse Mammary Stem Cell Enrichment Kit from StemCell
Technologies was used to obtain CD45, Ter119, and CD31 triple-
negative cell suspensions labeled with CD24 and CD49f. Briefly,
mammary epithelial cells were first incubated in a cocktail of
biotinylated CD45, Ter119, and CD31 antibodies, and then were
exposed to a biotin selection cocktail and removed using magnetic
nanoparticles. The remaining cells were labeled with DDAOG
(10 mm), CD24-PE, and CD49f-FITC for 30 min on ice, then
washed and resuspended in Hanks with 2% FBS and kept on ice.
Live cells were discriminated by propidium iodine exclusion. Cell
sorting and analysis was done by using the BD FACSCalibur Flow
Cytometer and Cell quest 5.2.1 software, respectively (BD
Biosciences). The FACS analysis described above was repeated
twice and included mammary epithelial cells collected from 4
Lrp6
+/2 and 5 Lrp6
+/+ females.
Expression profiling
Processed expression chip used in the GSE3744 dataset
contained multiple probes that mapped to LRP6. Therefore in
this dataset, the average LRP6 expression value was computed for
each sample and used in subsequent analysis. In the GSE3165
dataset, three related expression chips were used and a single LRP6
probe (NM_002336) was present across the majority of the chips.
Therefore, the expression value derived from the NM_00236
probe was used in subsequent analysis. Within each dataset, the
LRP6 expression values were partitioned into groups based on
tumor subtype and differences in expression between the basal-like
and non-basal like samples evaluated using a two-sided Welsh’s t-
test.
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